Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: END062
MIFTS: 47

Endometrial Hyperplasia

Categories: Cancer diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Endometrial Hyperplasia

About this section

MalaCards integrated aliases for Endometrial Hyperplasia:

Name: Endometrial Hyperplasia 12 54 44 15

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0080365
MeSH 44 D004714
Sources

Summaries for Endometrial Hyperplasia

About this section
Disease Ontology : 12 An uterine benign neoplasm that is characterized by excessive proliferation of the cells of the endometrium.

MalaCards based summary : Endometrial Hyperplasia is related to adenocarcinoma and endometrial adenocarcinoma. An important gene associated with Endometrial Hyperplasia is PGR (Progesterone Receptor), and among its related pathways/superpathways are Gene Expression and Endometrial cancer. The drugs Hormones and Hormone Antagonists have been mentioned in the context of this disorder. Affiliated tissues include breast, ovary and uterus, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 73 Endometrial hyperplasia is a condition of excessive proliferation of the cells of the endometrium, or... more...

Sources

Related Diseases for Endometrial Hyperplasia

About this section

Diseases related to Endometrial Hyperplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 330)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 31.1 PTEN MSH6 MSH2 MLH1 KRAS CTNNB1
2 endometrial adenocarcinoma 31.1 PTEN PGR MLH1 KRAS ESR2 ESR1
3 endometrial disease 31.0 PGR ESR1 CYP19A1
4 adenomyosis 30.9 PGR ESR2 ESR1 CYP19A1 CTNNB1
5 in situ carcinoma 30.9 PTEN PGR ESR1 CYP19A1 CTNNB1
6 estrogen excess 30.7 PTEN PGR ESR2 ESR1 CYP19A1
7 adenomyoma 30.7 PGR MLH1 CTNNB1
8 vaginal discharge 30.7 PGR ESR1 CYP19A1
9 hereditary nonpolyposis colon cancer 30.7 MSH6 MSH2 MLH1
10 endometriosis 30.6 PTEN PGR ESR2 ESR1 CYP19A1 CYP17A1
11 atypical polypoid adenomyoma 30.6 MLH1 CTNNB1
12 myoma 30.6 PGR KRAS ESR1 CYP19A1
13 infertility 30.5 PGR MLH1 ESR2 ESR1 CYP19A1 AR
14 vaginal cancer 30.3 PGR ESR2 ESR1
15 pelvic organ prolapse 30.3 PGR ESR2 ESR1
16 leiomyoma, uterine 30.3 PGR ESR1 CYP19A1
17 hyperandrogenism 30.2 CYP19A1 CYP17A1 AR
18 cervical adenocarcinoma 30.2 PTEN KRAS ESR1
19 lynch syndrome i 30.2 MSH6 MSH2 MLH1
20 endometrial stromal sarcoma 30.2 PGR ESR2 ESR1 CYP19A1
21 lynch syndrome 30.2 PTEN MSH6 MSH2 MLH1 KRAS CYP17A1
22 uterine carcinosarcoma 30.2 PTEN PGR ESR2 CTNNB1
23 bone resorption disease 30.2 ESR2 ESR1 CYP19A1 CTNNB1
24 carcinosarcoma 30.1 PTEN PGR KRAS CTNNB1
25 adenosarcoma 30.1 PGR MKI67 ESR1
26 leiomyoma 30.0 PGR MKI67 ESR2 ESR1 CYP19A1 CYP17A1
27 endometrial cancer 29.9 PTEN PGR NCOA3 MSH6 MSH2 MMP26
28 estrogen-receptor positive breast cancer 29.6 PGR NCOA3 ESR2 ESR1 CYP19A1 AR
29 uterine corpus cancer 29.6 PTEN PGR MSH6 MSH2 MLH1 KRAS
30 adenoma 29.6 MSH6 MSH2 MLH1 MKI67 KRAS CTNNB1
31 ovarian disease 29.5 PTEN PGR ESR2 ESR1 CYP19A1 CYP17A1
32 breast cancer 27.4 PTEN PGR NCOR1 NCOA3 NCOA1 MSH6
33 polycystic ovary syndrome 10.5
34 breast duct papilloma 10.5 PTEN PGR
35 glassy cell carcinoma of the cervix 10.5 PGR ESR1
36 breast intraductal papillomatosis 10.5 PGR ESR1
37 nipple carcinoma 10.5 PGR ESR1
38 bartholin's gland adenoma 10.5 PGR ESR1
39 bartholin's gland adenoid cystic carcinoma 10.5 PGR ESR1
40 uterine corpus adenosarcoma 10.5 PGR ESR1
41 bartholin's gland benign neoplasm 10.5 PGR ESR1
42 chronic tympanitis 10.5 PGR ESR1
43 vestibular gland benign neoplasm 10.5 PGR ESR1
44 granulomatous endometritis 10.5 PGR ESR1
45 vulvar syringoma 10.5 PGR ESR1
46 lung leiomyoma 10.5 PGR ESR1
47 subserous uterine fibroid 10.5 PGR CYP19A1
48 nonmucinous bronchioloalveolar adenocarcinoma 10.5 ESR2 ESR1
49 diffuse peritoneal leiomyomatosis 10.5 PGR CYP19A1
50 adult type testicular granulosa cell tumor 10.5 PGR ESR1

Graphical network of the top 20 diseases related to Endometrial Hyperplasia:



Diseases related to Endometrial Hyperplasia
Sources

Symptoms & Phenotypes for Endometrial Hyperplasia

About this section

GenomeRNAi Phenotypes related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

26 (show all 38)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 10.29 KRAS
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.29 KRAS
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-118 10.29 CDK2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 10.29 NCOR1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-122 10.29 CDK2
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-13 10.29 CDK2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 10.29 CABLES1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 10.29 CDK2
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.29 KRAS
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-147 10.29 NCOR1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-157 10.29 CDK2
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.29 KRAS
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-168 10.29 KRAS
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.29 KRAS
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.29 KRAS
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-194 10.29 CABLES1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-196 10.29 KRAS
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.29 KRAS
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-23 10.29 KRAS
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-25 10.29 CDK2
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.29 KRAS
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.29 KRAS
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-4 10.29 CABLES1 MSH2
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-41 10.29 CDK2
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-43 10.29 CDK2 MSH2
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-47 10.29 NCOR1
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 10.29 CDK2 KRAS
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 10.29 KRAS
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.29 CABLES1 CDK2 KRAS
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-54 10.29 MSH2
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-57 10.29 CDK2
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-63 10.29 MSH2
33 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.29 KRAS
34 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 10.29 CABLES1
35 Decreased shRNA abundance (Z-score < -2) GR00366-A-83 10.29 NCOR1
36 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.29 NCOR1
37 Decreased shRNA abundance (Z-score < -2) GR00366-A-93 10.29 CDK2 KRAS
38 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.02 ESR1 ESR2 MKI67 MSH2 PTEN

MGI Mouse Phenotypes related to Endometrial Hyperplasia:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.49 AR CABLES1 CTNNB1 CYP17A1 CYP19A1 ESR1
2 cellular MP:0005384 10.47 AR CDK2 CTNNB1 CYP17A1 CYP19A1 ESR1
3 homeostasis/metabolism MP:0005376 10.47 AR CDK2 CTNNB1 CYP17A1 CYP19A1 ESR1
4 endocrine/exocrine gland MP:0005379 10.45 AR CABLES1 CDK2 CTNNB1 CYP19A1 ESR1
5 immune system MP:0005387 10.43 AR CDK2 CTNNB1 CYP19A1 ESR1 ESR2
6 hematopoietic system MP:0005397 10.42 AR CDK2 CTNNB1 CYP19A1 ESR1 ESR2
7 integument MP:0010771 10.39 AR CDK2 CTNNB1 CYP19A1 ESR1 ESR2
8 growth/size/body region MP:0005378 10.38 AR CDK2 CTNNB1 CYP17A1 CYP19A1 ESR1
9 cardiovascular system MP:0005385 10.35 AR CDK2 CTNNB1 CYP17A1 CYP19A1 ESR1
10 mortality/aging MP:0010768 10.3 AR CDK2 CTNNB1 CYP17A1 ESR1 ESR2
11 digestive/alimentary MP:0005381 10.29 AR CTNNB1 CYP19A1 ESR1 ESR2 KRAS
12 embryo MP:0005380 10.28 AR CDK2 CTNNB1 ESR1 KRAS NCOA1
13 adipose tissue MP:0005375 10.27 AR CYP17A1 CYP19A1 ESR1 ESR2 NCOA1
14 liver/biliary system MP:0005370 10.22 AR CDK2 CTNNB1 CYP19A1 ESR1 ESR2
15 neoplasm MP:0002006 10.22 AR CABLES1 CDK2 CTNNB1 ESR1 ESR2
16 muscle MP:0005369 10.17 AR CDK2 CTNNB1 CYP19A1 ESR1 ESR2
17 nervous system MP:0003631 10.15 AR CABLES1 CTNNB1 CYP19A1 ESR1 ESR2
18 hearing/vestibular/ear MP:0005377 10.1 CTNNB1 CYP17A1 CYP19A1 ESR2 KRAS NCOA3
19 normal MP:0002873 10.06 AR CTNNB1 CYP19A1 ESR1 ESR2 KRAS
20 limbs/digits/tail MP:0005371 10.04 AR CTNNB1 ESR1 ESR2 KRAS PGR
21 reproductive system MP:0005389 9.83 AR CABLES1 CDK2 CTNNB1 CYP17A1 CYP19A1
22 renal/urinary system MP:0005367 9.81 AR CTNNB1 CYP19A1 ESR1 ESR2 KRAS
23 pigmentation MP:0001186 9.73 AR CTNNB1 CYP19A1 KRAS PTEN RBP1
24 skeleton MP:0005390 9.36 AR CTNNB1 CYP17A1 CYP19A1 ESR1 ESR2
Sources

Drugs & Therapeutics for Endometrial Hyperplasia

About this section

Drugs for Endometrial Hyperplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 48)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Hormones Phase 4
2 Hormone Antagonists Phase 4
3 Estrogens Phase 4
4 BIRC5 protein, human Phase 4
5 Estrogens, Conjugated (USP) Phase 4
6
Bazedoxifene Approved, Investigational Phase 3 198481-32-2
7
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
8
Levonorgestrel Approved, Investigational Phase 2, Phase 3 797-63-7, 17489-40-6 13109
9
Progesterone Approved, Vet_approved Phase 2, Phase 3 57-83-0 5994
10
Dydrogesterone Approved, Investigational, Withdrawn Phase 2, Phase 3 152-62-5 9051
11 Raloxifene Hydrochloride Phase 3
12 Estrogen Receptor Modulators Phase 3
13 Progestins Phase 2, Phase 3
14 Anticholesteremic Agents Phase 2, Phase 3
15 Rosuvastatin Calcium Phase 2, Phase 3 147098-20-2
16 Antimetabolites Phase 2, Phase 3
17 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2, Phase 3
18 Hypolipidemic Agents Phase 2, Phase 3
19 Lipid Regulating Agents Phase 2, Phase 3
20 Calcium, Dietary Phase 2, Phase 3
21
Calcium Nutraceutical Phase 2, Phase 3 7440-70-2 271
22
Polyestradiol phosphate Approved Phase 2 28014-46-2
23
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
24
Norethindrone Approved Phase 2 68-22-4 6230
25
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
26
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
27
Exemestane Approved, Investigational Phase 2 107868-30-4 60198
28
Medroxyprogesterone acetate Approved, Investigational Phase 2 71-58-9
29
Genistein Investigational Phase 2 446-72-0 5280961
30 Estradiol 3-benzoate Phase 2
31 Estradiol 17 beta-cypionate Phase 2
32 Norethindrone Acetate Phase 2
33 Soy Bean Phase 2
34 Immunosuppressive Agents Phase 2
35 Immunologic Factors Phase 2
36 Estrogen Antagonists Phase 2
37 Estrogen Receptor Antagonists Phase 2
38 Aromatase Inhibitors Phase 2
39
Medroxyprogesterone Phase 2 520-85-4 10631
40 Contraceptive Agents, Male Phase 2
41
Misoprostol Approved 59122-46-2 5282381
42
Tamoxifen Approved 10540-29-1 2733526
43
Ethinyl Estradiol Approved Early Phase 1 57-63-6 5991
44 Anesthetics
45 insulin Early Phase 1
46 Contraceptives, Oral, Combined Early Phase 1
47 Insulin, Globin Zinc Early Phase 1
48 Ulipristal acetate 126784-99-4

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 The Effect of Metformin and Medroxyprogesterone Acetate on Apoptotic Signaling Pathways in Wistar-Albino Rats With Induced Endometrial Hyperplasia Completed NCT02872818 Phase 4 17β estradiol hemihydrate;Metformin;medroxyprogesterone acetate
2 A Multicenter Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia Completed NCT01074892 Phase 4 Provera (medroxyprogesterone/progestin);Provera (medroxyprogesterone)
3 Randomized, Blinded Trial Comparing Vaginal Estrogens on Pelvic Organ Prolapse Patients Completed NCT03032848 Phase 4 Conjugated Estrogen;Promestriene;Estriol;Vaginal Moisturizer - Cream
4 A Double-Blind, Randomized, Placebo- and Active-Controlled Safety and Efficacy Study of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women Completed NCT00675688 Phase 3 Bazedoxifene/Conjugate Estrogens (CE);Raloxifene;Placebo
5 A Double-Blind, Randomized, Placebo- And Active-Controlled Efficacy And Safety Study Of Bazedoxifene/Conjugated Estrogens Combinations For Prevention Of Endometrial Hyperplasia And Prevention Of Osteoporosis In Postmenopausal Women Completed NCT00242710 Phase 3 Bazedoxifene/Conjugated Estrogen;Bazedoxifene/Conjugated Estrogen;CE 0.45 mg/MPA 1.5mg
6 Megestrol Acetate Plus LNG-IUS to Megestrol Acetate or LNG-IUS in Young Women With Endometrial Atypical Hyperplasia Completed NCT03241888 Phase 2, Phase 3 Megestrol Acetate
7 A Double-Blind, Randomized, Placebo And Active- Controlled Efficacy And Safety Study Of The Effects Of Bazedoxifene/Conjugated Estrogens Combinations On Endometrial Hyperplasia And Prevention Of Osteoporosis In Postmenopausal Women Completed NCT00808132 Phase 3 bazedoxifene 20 mg/ conjugated estrogens 0.45 mg;bazedoxifene 20 mg/ conjugated estrogens 0.625 mg;bazedoxifene 20 mg;conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg;Placebo
8 Operational Hysteroscopy Versus Traditional Surgery: Costs and Health Benefits Completed NCT00490087 Phase 3
9 The Efficacy of Levonorgestrel Intrauterine System Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia. A Randomized Controlled Trial. Recruiting NCT04385667 Phase 2, Phase 3 Oral Megesterol 160 mg daily
10 Medroxyprogesterone Acetate (MPA) Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia Recruiting NCT03675139 Phase 2, Phase 3 Medroxyprogesterone Acetate;Dydrogesterone 10 MG
11 Comparing Metformin Plus Megestrol Acetate With Megestrol Acetate Alone as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia Recruiting NCT04607252 Phase 2, Phase 3 Metformin plus Megestrol acetate;Megestrol Acetate
12 Megestrol Acetate Plus Rosuvastatin Versus Megestrol Acetate in Young Women With Atypical Endometrial Hyperplasia Recruiting NCT04491682 Phase 2, Phase 3 Megestrol Acetate;Rosuvastatin
13 Value of Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Fertility-preserving Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma Recruiting NCT03463252 Phase 2, Phase 3 Progesterone;GnRH agonist
14 Megestrol Acetate Versus Liraglutide Plus Megestrol Acetate in Obese Women With Endometrial Atypical Hyperplasia: A Randomized Controlled Pilot Clinical Study Withdrawn NCT04683237 Phase 2, Phase 3 Liraglutide Injection;Megestrol Acetate 160 MG
15 Efficacy & Tolerability of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen Replacement Therapy - Phase II Comparative Study Unknown status NCT00919919 Phase 2 progesterone;activella
16 Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System:Single Arm, Prospective Multicenter Study: Korean Gynecologic Oncology Group Study (KGOG2006) Unknown status NCT01234818 Phase 2
17 Surgicel® Versus Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding (HMB): Randomised Controlled Trial Unknown status NCT03176992 Phase 2 SURGICEL®
18 The Effect of Neoadjuvant Depot Medroxyprogesterone Acetate on Glandular Cellularity in Women With Complex Atypical Hyperplasia or Grade 1-2 Endometrial Adenocarcinoma Awaiting Hysterectomy Unknown status NCT02335203 Phase 2 Depot medroxyprogesterone acetate
19 Prospective Trial of Conservative Management of Atypical Endometrial Hyperplasia and Well to Moderately Differentiated Endometrial Carcinoma Using Megestrol Acetate Completed NCT00483327 Phase 2 Megestrol Acetate
20 Effect of Genistein on Endometrial Hyperplasia Completed NCT00453960 Phase 2 Norethisterone Acetate
21 Soy Estrogen Alternative Study (SEA) Completed NCT00000612 Phase 2 estrogens, conjugated
22 Phase II Study of the Levonorgestrel Intrauterine Device Alone or in Combination With the mTORC1 Inhibitor, Everolimus, for the Treatment of Complex Atypical Hyperplasia and Stage Ia Grade 1 Endometrial Cancer Recruiting NCT02397083 Phase 2 Everolimus
23 A Phase II Randomised Clinical Trial of Mirena® ± Metformin ± Weight Loss Intervention in Patients With Early Stage Cancer of the Endometrium Active, not recruiting NCT01686126 Phase 2 Levonorgestrel;Metformin
24 A Phase II Study of the Levonorgestrel Intrauterine Device (Mirena) to Treat Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Carcinoma Active, not recruiting NCT00788671 Phase 2
25 Pilot Study of Daily Exemestane in Women With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer Active, not recruiting NCT03300557 Phase 2 Exemestane
26 A Randomized Phase II Evaluation of Continuous Progestin Therapy vs. Sequential Progestin Therapy in the Treatment of Endometrial Intraepithelial Neoplasia (EIN) From a Referred Cohort of Atypical Endometrial Hyperplasia (AEH) or EIN Patients That Desire Uterine Preservation Terminated NCT00503581 Phase 2 Megestrol Acetate
27 A Two-Part Study of the Treatment of Atypical Endometrial Hyperplasia: Part A: A Prospective Study of Immediate Hysterectomy; Part B: A Randomized Phase II Study of Medroxyprogesterone Acetate Versus Depoprovera Terminated NCT00003179 Phase 2 medroxyprogesterone
28 Levonorgestrel Containing Intrauterine Device in the Treatment of Endometrial Hyperplasia Without Atypia Withdrawn NCT00123175 Phase 1, Phase 2
29 A Phase II Head-to-Head Comparison of Fertility-Sparing Approaches to Treat Complex Atypical Hyperplasia of the Edometrium: Megestrol Versus Levonorgestrel-Releasing Intrauterine System (LNG-IUS) Withdrawn NCT01943058 Phase 2 megestrol acetate
30 Comparison of Dilatation & Curettage and Endometrial Aspiration Biopsy Accuracy in Patients Treated With Progestin for Endometrial Hyperplasia: A Korean Gynecologic Oncology Group Study Unknown status NCT02412072
31 Role of Senescence in the Development of Endometrial Cancer Unknown status NCT03338985
32 The Relation Between Serum Irisin Hormone Level and Endometrial Hyperplasia Unknown status NCT02903797
33 Concurrent Endometrial Cancer With Endometrial Hyperplasia or Endometrial Intraepithelial Neoplasia - Focus on Risk Factors Analysis Unknown status NCT01273636
34 Screening for Endometrial Abnormalities in Overweight and Obese Women Completed NCT01922778
35 LNG-IUS or Norethisterone Acetate for Treatment of Non-atypical Endometrial Hyperplasia in Perimenopausal Women Completed NCT01499602 LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland;Norethisterone Acetate tablets
36 Metformin for the Treatment of Endometrial Hyperplasia Completed NCT01685762 Early Phase 1 Metformin
37 Referral of Obese Endometrial Cancer Survivors to a Bariatric Specialist and a Healthier Survivorship: A Prospective Intervention Cohort Study Completed NCT02342730
38 Vaginal Micronized Progesterone or Levonorgestrel-releasing Intrauterine System (LNG-IUS) for Treatment of Non-atypical Endometrial Hyperplasia: A Prospective Randomized Trial Completed NCT03992937 Vaginal Micronized Progesterone
39 Correlation Between Hysteroscopic Diagnosis of Endometrial Hyperplasia and Histopathological Examination: a Prospective Cohort Study Completed NCT03917147
40 Women With Asymptomatic Endometrial Hyperplasia Completed NCT02100137
41 Preliminary Study of Endometrial Hyperplasia: Groundwork for a Study to Define an Optimal Classification of Endometrial Carcinoma Precursors Completed NCT00339651
42 Office Hysteroscopy in the Infertility Work-out: the Role of Endometrial Hyperplasia in Southern Italian Women Completed NCT03965585
43 Pilot-study of OSCAR ENDO One Stop Assessment of Risk for Endometrial Hyperplasia and Cancer Completed NCT01961102
44 Use of the Electronic Catheter Stethoscope for the Detection of Urinary Tract Injury During Gynecologic Surgery Completed NCT01463462
45 Mirena Observational Program Completed NCT00883662 Levonorgestrel (Mirena, BAY86-5028)
46 Pilot Study: Can the iKnife (Rapid Evaporative Ionisation Mass Spectrometry) Distinguish Between Normal and Malignant Endometrial Tissue? Completed NCT03207074
47 Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age Recruiting NCT03905941 Early Phase 1 Metformin;Oral combined hormonal contraceptives
48 Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC) Recruiting NCT00892866
49 Long-term Observation of Symptomatic Women With Uterine Fibroids Who Have Been Treated With Ulipristal Acetate: Findings on Symptomatology, Morphological Structure, Endometrial Patterns Recruiting NCT03972917
50 Pilot Study: Can Ultrasound Guided Biopsy be Used as an Alternative to Hysteroscopy in the Detection of Endometrial Cancer? Recruiting NCT03207126

Search NIH Clinical Center for Endometrial Hyperplasia

Cochrane evidence based reviews: endometrial hyperplasia

Sources

Genetic Tests for Endometrial Hyperplasia

About this section
Sources

Anatomical Context for Endometrial Hyperplasia

About this section

MalaCards organs/tissues related to Endometrial Hyperplasia:

40
Breast, Ovary, Uterus, Cervix, Colon, Pituitary, Liver
Sources

Publications for Endometrial Hyperplasia

About this section

Articles related to Endometrial Hyperplasia:

(show top 50) (show all 3164)
# Title Authors PMID Year
1
Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. 61 54
20107426 2010
2
Prognostic significance of estrogen and progesterone receptor expression in LNG-IUS (Mirena) treatment of endometrial hyperplasia: an immunohistochemical study. 54 61
20199355 2010
3
Involvement of Akt, Ras and cell cycle regulators in the potential development of endometrial hyperplasia in women with polycystic ovarian syndrome. 54 61
19631369 2009
4
Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET. 54 61
19759112 2009
5
[Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions]. 54 61
20079187 2009
6
Utility of PTEN expression of endometrial "surface epithelial changes" and underlying atypical endometrial hyperplasia. 54 61
19696618 2009
7
Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. 54 61
19301987 2009
8
Correlation between PTEN expression and PI3K/Akt signal pathway in endometrial carcinoma. 54 61
19224164 2009
9
Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma. 54 61
19419940 2009
10
Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions. 61 54
18720455 2008
11
Detection of PTEN immunoreactivity in endometrial hyperplasia and adenocarcinoma. 54 61
18788685 2008
12
Labial aggressive angiomyxoma associated with endometrial hyperplasia and uterine leiomyoma: a case report and review of the literature. 61 54
18839858 2008
13
Immunohistochemical markers in endometrial hyperplasia: is there a panel with promise? A review. 54 61
18528284 2008
14
PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. 61 54
18632658 2008
15
From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. 54 61
18287870 2008
16
Expression of retinoic acid receptors in human endometrial carcinoma. 54 61
18271925 2008
17
Loss of phosphatase and tensin homologue deleted on chromosome 10 and phosphorylation of mammalian target of rapamycin are associated with progesterone refractory endometrial hyperplasia. 54 61
17466036 2008
18
Letrozole as primary therapy for endometrial hyperplasia in young women. 54 61
17889878 2008
19
Progressive derailment of cell cycle regulators in endometrial carcinogenesis. 61 54
17483252 2008
20
Distinctive FDG and FES accumulation pattern of two tamoxifen-treated patients with endometrial hyperplasia. 54 61
18250990 2008
21
Coexpression index of estrogen receptor alpha mRNA isoforms in simple, complex hyperplasia without atypia, complex atypical hyperplasia and adenocarcinoma. 61 54
17561234 2007
22
Immunoprofile of endocervical and endometrial stromal cells and its potential application in localization of tumor involvement. 54 61
17197901 2007
23
Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer. 54 61
17089036 2006
24
Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: Correlation with clinicopathologic parameters and biomarkers. 54 61
16980945 2006
25
Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. 54 61
17085648 2006
26
Androgen and estrogen receptors and co-regulators levels in endometria from patients with polycystic ovarian syndrome with and without endometrial hyperplasia. 54 61
16677694 2006
27
[Promoters of genes MTHFR from patients with hyperhomocysteinemia and PTEN from patients with malignant and benign endometrial and ovarian tumors]. 61 54
16909866 2006
28
[Expressions of aromatase protein and sex hormone receptor in endometrial lesions]. 61 54
16831363 2006
29
[Expression and clinical significance of Beclin1 and PTEN in endometrial carcinoma]. 61 54
16764775 2006
30
Cellular retinol binding protein-1 expression in endometrial hyperplasia and carcinoma: diagnostic and possible therapeutic implications. 54 61
16575402 2006
31
Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. 54 61
16325240 2006
32
Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. 61 54
16633364 2006
33
The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer. 61 54
16493257 2006
34
CYP17 genetic polymorphism in patients with endometrial hyperplasia and cancer. 54 61
16515644 2006
35
Immunohistochemical evaluation of PTEN protein in patients with endometrial intraepithelial neoplasia compared to endometrial adenocarcinoma and proliferative phase endometrium. 54 61
17009632 2006
36
Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia. 61 54
16099019 2005
37
Eosinophilic cell change of the endometrium: a possible relationship to mucinous differentiation. 61 54
15803181 2005
38
Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma. 54 61
15882182 2005
39
Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium. 61 54
15863148 2005
40
Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression. 61 54
15948123 2005
41
Immunohistochemical detection of human telomerase reverse transcriptase (hTERT), topoisomerase IIalpha expression, and apoptosis in endometrial adenocarcinoma and atypical hyperplasia. 54 61
15782075 2005
42
Human telomerase RNA as endogenous control in endometrial tissue. 61 54
15823123 2005
43
Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables. 54 61
14740230 2005
44
Disorders in cytokine gene expression in endometrial hyperplasia and effect of hormone therapy. 54 61
16027816 2005
45
PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma. 54 61
15583796 2005
46
Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium. 61 54
15800680 2005
47
Differences in serum bisphenol a concentrations in premenopausal normal women and women with endometrial hyperplasia. 61 54
15644579 2004
48
Cellular retinol-binding protein-1 expression in endometrial stromal cells: physiopathological and diagnostic implications. 61 54
15500655 2004
49
Genetic derangements in the tumor suppressor gene PTEN in endometrial precancers as prognostic markers for cancer development: a population-based study from northern Norway with long-term follow-up. 61 54
15385114 2004
50
Matrix metalloproteinase-26 (matrilysin-2) expression is high in endometrial hyperplasia and decreases with loss of histological differentiation in endometrial cancer. 54 61
15350356 2004
Sources

Variations for Endometrial Hyperplasia

About this section
Sources

Expression for Endometrial Hyperplasia

About this section
Search GEO for disease gene expression data for Endometrial Hyperplasia.
Sources

Pathways for Endometrial Hyperplasia

About this section

Pathways related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Gene Expression 65
Show member pathways
 13.78 PTEN PGR NCOR1 NCOA1 MSH2 MLH1
2
Endometrial cancer 36
Show member pathways
 12.77 PTEN MSH6 MSH2 MLH1 KRAS CTNNB1
3
Chks in Checkpoint Regulation 63
Show member pathways
 12.66 MSH6 MSH2 ESR2 ESR1 CDK2
4
Glioma 36
Show member pathways
 12.61 PTEN NCOR1 NCOA3 MSH6 KRAS ESR2
5
Gastric cancer 36
Show member pathways
 12.52 PTEN PGR NCOA3 NCOA1 MLH1 KRAS
6
DNA Damage 4
12.5 MSH6 MSH2 MLH1 MKI67 CDK2
7
Prolactin Signaling Pathway 1 36
Show member pathways
 12.47 PTEN NCOA1 KRAS ESR2 ESR1 CYP17A1
8
Pathways in cancer 36
12.46 PTEN NCOA3 NCOA1 MSH6 MSH2 MLH1
9
Chromatin Regulation / Acetylation 4
12.37 NCOR1 NCOA3 NCOA1 AR
10
Oocyte meiosis 36
Show member pathways
 12.32 PGR KRAS CDK2 AR
11
Development Ligand-independent activation of ESR1 and ESR2 23
Show member pathways
 12.29 NCOR1 NCOA3 NCOA1 ESR2 ESR1
12
Translation Non-genomic (rapid) action of Androgen Receptor 23
Show member pathways
 12.28 PTEN NCOR1 NCOA1 CTNNB1 AR
13
Colorectal Cancer Metastasis 63
12.16 MSH6 MSH2 MLH1 KRAS CTNNB1
14
Estrogen signaling pathway (KEGG) 36
12.07 PGR NCOA3 NCOA1 KRAS ESR2 ESR1
15
Thyroid hormone signaling pathway 36
11.99 NCOR1 NCOA3 NCOA1 KRAS ESR1 CTNNB1
16
Glioblastoma Multiforme 63
11.96 PTEN KRAS CTNNB1 CDK2
17
Signaling by ERBB4 65
Show member pathways
 11.95 PGR NCOR1 KRAS ESR1
18
TGF-beta Signaling Pathways 64
11.87 KRAS ESR2 ESR1 AR
19
Mismatch repair 1 65 36
Show member pathways
 11.83 MSH6 MSH2 MLH1
20
Nuclear Receptor transcription pathway 65
Show member pathways
 11.83 PGR ESR2 ESR1 AR
21
Androgen receptor signaling pathway 1
11.8 PTEN NCOR1 NCOA3 NCOA1 CTNNB1 AR
22
Retinoblastoma (RB) in Cancer 1
11.79 RBP1 MSH6 CDK2
23
Regulation of nuclear SMAD2/3 signaling 1
11.78 NCOR1 NCOA1 ESR1 CDK2 AR
24
Platinum drug resistance 36
11.7 MSH6 MSH2 MLH1
25
Transcription Ligand-dependent activation of the ESR1/SP pathway 23
Show member pathways
 11.68 NCOA3 NCOA1 ESR1
26
Cell cycle ESR1 regulation of G1/S transition 23
Show member pathways
 11.57 PGR NCOR1 NCOA3 NCOA1 ESR1 CDK2
27
Integrated Breast Cancer Pathway 1
11.51 PTEN NCOA3 MSH6 MSH2 KRAS ESR1
28
Notch-mediated HES/HEY network 1
11.5 NCOR1 NCOA1 AR
29
Aryl Hydrocarbon Receptor 1
11.49 KRAS ESR1 CDK2
30
Integrated Cancer Pathway 1
11.49 PTEN MSH6 MSH2 CDK2
31
FOXA1 transcription factor network 1
Show member pathways
 11.47 NCOA3 ESR1 AR
32
Platinum Pathway, Pharmacokinetics/Pharmacodynamics 60
11.26 MSH6 MSH2 MLH1
33
Ovarian Infertility Genes 1
11.22 PGR NCOR1 MLH1 ESR2 CYP19A1
34
Retinoic acid receptors-mediated signaling 1
11.18 RBP1 NCOA3 NCOA1
35
AHR Pathway 63
11.17 NCOA3 NCOA1 ESR1
36
MNAR-PELP1 and Estrogen Receptor Interaction 63
11.12 KRAS ESR2 ESR1
37
Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics 60
10.29 ESR2 ESR1 CYP19A1
Sources

GO Terms for Endometrial Hyperplasia

About this section

Cellular components related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.24 PTEN PGR NCOR1 NCOA3 NCOA1 MSH6
2 cytosol GO:0005829 10.22 RBP1 PTEN PGR NCOR1 NCOA3 NCOA1
3 chromatin GO:0000785 9.92 PGR NCOR1 NCOA3 NCOA1 MSH6 ESR2
4 nucleoplasm GO:0005654 9.5 RBP1 PTEN PGR NCOR1 NCOA3 NCOA1
5 condensed chromosome GO:0000793 9.33 MLH1 MKI67 CDK2
6 MutSalpha complex GO:0032301 9.26 MSH6 MSH2
7 mismatch repair complex GO:0032300 9.13 MSH6 MSH2 MLH1

Biological processes related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.16 PGR NCOA3 NCOA1 ESR2 ESR1 CTNNB1
2 negative regulation of transcription by RNA polymerase II GO:0000122 10.1 NCOR1 ESR2 ESR1 CTNNB1 CDK2 AR
3 positive regulation of transcription, DNA-templated GO:0045893 10.08 NCOA1 ESR2 ESR1 CTNNB1 CDK2 AR
4 positive regulation of cell proliferation GO:0008284 10.04 PTEN KRAS CTNNB1 CDK2 AR
5 positive regulation of DNA-binding transcription factor activity GO:0051091 9.78 PTEN ESR2 ESR1 CTNNB1
6 male gonad development GO:0008584 9.76 NCOA1 MSH2 ESR1 AR
7 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.73 MSH6 MSH2 MLH1
8 cellular response to estradiol stimulus GO:0071392 9.71 NCOA3 ESR2 ESR1
9 mismatch repair GO:0006298 9.67 MSH6 MSH2 MLH1
10 regulation of synaptic transmission, GABAergic GO:0032228 9.65 PTEN KRAS
11 transcription initiation from RNA polymerase II promoter GO:0006367 9.65 PTEN PGR ESR2 ESR1 AR
12 locomotor rhythm GO:0045475 9.64 PTEN NCOR1
13 protein localization to chromatin GO:0071168 9.64 MSH2 ESR1
14 cellular process GO:0009987 9.63 CTNNB1 AR
15 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.62 NCOR1 ESR1
16 positive regulation of isotype switching to IgG isotypes GO:0048304 9.62 MSH2 MLH1
17 prostate gland growth GO:0060736 9.6 PTEN AR
18 male mating behavior GO:0060179 9.59 PTEN NCOA1
19 positive regulation of helicase activity GO:0051096 9.58 MSH6 MSH2
20 positive regulation of isotype switching to IgA isotypes GO:0048298 9.58 MSH2 MLH1
21 intracellular estrogen receptor signaling pathway GO:0030520 9.58 ESR2 ESR1 AR
22 maintenance of DNA repeat elements GO:0043570 9.57 MSH6 MSH2
23 epithelial cell differentiation involved in prostate gland development GO:0060742 9.55 CTNNB1 AR
24 response to estradiol GO:0032355 9.55 PTEN NCOA1 ESR1 CYP19A1 CTNNB1
25 isotype switching GO:0045190 9.54 MSH6 MSH2 MLH1
26 positive regulation of epithelial cell proliferation involved in prostate gland development GO:0060769 9.52 CTNNB1 AR
27 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.51 PGR AR
28 somatic hypermutation of immunoglobulin genes GO:0016446 9.5 MSH6 MSH2 MLH1
29 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.43 MSH2 MLH1
30 somatic recombination of immunoglobulin gene segments GO:0016447 9.13 MSH6 MSH2 MLH1
31 intracellular steroid hormone receptor signaling pathway GO:0030518 8.92 PGR ESR2 ESR1 AR

Molecular functions related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 10.23 PGR NCOR1 NCOA1 MSH6 MSH2 MKI67
2 lipid binding GO:0008289 9.91 RBP1 PTEN PGR ESR2 ESR1 AR
3 chromatin binding GO:0003682 9.87 NCOA1 MSH6 MSH2 MLH1 ESR1 CTNNB1
4 beta-catenin binding GO:0008013 9.77 ESR1 CTNNB1 AR
5 ATPase binding GO:0051117 9.76 PGR ESR1 AR
6 estrogen receptor binding GO:0030331 9.7 NCOA1 ESR1 CTNNB1
7 nuclear receptor activity GO:0004879 9.67 PGR ESR2 ESR1 AR
8 steroid hormone receptor activity GO:0003707 9.63 PGR ESR2 ESR1
9 mismatched DNA binding GO:0030983 9.58 MSH6 MSH2 MLH1
10 MutLalpha complex binding GO:0032405 9.57 MSH6 MSH2
11 oxidized purine DNA binding GO:0032357 9.56 MSH6 MSH2
12 steroid binding GO:0005496 9.56 PGR ESR2 ESR1 AR
13 RNA polymerase II transcription coactivator binding GO:0001225 9.55 PGR AR
14 estrogen receptor activity GO:0030284 9.54 ESR2 ESR1
15 estrogen response element binding GO:0034056 9.51 ESR2 ESR1
16 single guanine insertion binding GO:0032142 9.49 MSH6 MSH2
17 single thymine insertion binding GO:0032143 9.48 MSH6 MSH2
18 nuclear hormone receptor binding GO:0035257 9.46 NCOR1 NCOA3 NCOA1 CTNNB1
19 enzyme binding GO:0019899 9.32 PTEN PGR NCOA1 MSH6 MSH2 MLH1
20 guanine/thymine mispair binding GO:0032137 9.13 MSH6 MSH2 MLH1
Sources

Sources for Endometrial Hyperplasia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....